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p57 in Hydatidiform Moles: Evaluation of Antibodies and
Expression in Various Cell Types
Helle Lund, MD,*† Søren Nielsen, HT,* Anni Grove, MD,* Mogens Vyberg, MD,*†
and Lone Sunde, MD‡§
Abstract: The protein p57 is encoded by CDKN1C. This gene is
known to be paternally imprinted and maternally expressed in
cytotrophoblasts and villous stromal cells. We present a method
for evaluating p57 antibodies (Abs) in hydatidiform mole (HM)
and demonstrate the results for 4 p57 Abs in various cell types.
Five cases of complete HM, diploid with 2 paternal genome sets
(CHM;PP), 5 cases of partial HM, triploid with 2 paternal and 1
maternal genome sets (PHM;PPM), and 5 cases of non-HM,
with diploid biparental genomes (non-HM;PM) were stained
with p57 Abs: 57P06, EP183, KP10, and KP39. Assessment of
the fraction of nuclei stained, and the intensity of staining of the
nuclei and cytoplasm was performed. For evaluation of the Abs,
the observations in cytotrophoblasts, villous stromal cells, ma-
ternal decidual cells, and intermediate trophoblasts were scored.
The fraction of stained nuclei in cytotrophoblasts and villous
stromal cells and the staining of cytoplasm showed to be im-
portant parameters in the evaluation of the Abs. 57P06 was
evaluated as optimal. KP10 showed moderate cytoplasmatic
staining in maternal decidual cells and intermediate trophoblasts,
and was evaluated as good. EP183 was evaluated as poor, pri-
marily due to nuclear staining in ≥ 10% of the villous stromal
cells in CHM;PP. KP39 was evaluated as poor, primarily due
to strong cytoplasmatic staining in some cytotrophoblasts and
villous stromal cells. A structured testing of p57 for diagnosing
HM is recommended. No nuclear staining was observed in
syncytiotrophoblasts of CHM;PP, indicating that in syncytio-
trophoblasts also, CDKN1C is paternally imprinted.
Key Words: hydatidiform mole, antibody, immunohistochemistry,
imprinting, syncytiotrophoblast
(Appl Immunohistochem Mol Morphol 2020;28:694–701)
Hydatidiformmole (HM) is an abnormal human pregnancythat imposes a significant risk of gestational trophoblastic
neoplasia (GTN). On the basis of morphologic criteria, HM
can be classified as complete (CHM) or partial (PHM).1–3 The
majority of CHM cases are diploid with 2 paternal (P) genome
sets (CHM;PP), whereas the majority of PHM cases are trip-
loid with 2 paternal genome sets and 1 maternal (M) genome
set (PHM;PPM). 4–7 Subclassification of HM is important, as
the risk of GTN is significantly higher in CHM;PP than in
PHM;PPM.6,8 As regards prognosis, genetic classification is
superior to morphologic classification.6,7 However, analysis
of ploidy and parental origin is costly and ideally performed
on unfixed tissue, which is often not available. In contrast,
immunohistochemical (IHC) analysis of nuclear p57 expression
is cheap and can be performed on formalin-fixed tissue.9–13 p57
is the product of the gene CDKN1C, located on chromosome
11p15.5. This gene is paternally imprinted and maternally ex-
pressed in cytotrophoblasts and villous stromal cells.14 Thus,
p57 staining of nuclei of the cytotrophoblasts and villous
stromal cells should be negative in CHM;PP, and positive in
PHM;PPM, and in nonmolar pregnancy products, which
possess 1 paternal and 1 maternal genome set (non-HM;PM).
The use of ancillary techniques, such as IHC of p57 to
refine the diagnosis of HM, is generally recommended.10,12,15–20
The quality of the p57 staining is important, as both false-
negative and false-positive results may lead to misclassification
of HM. In the Nordic Immunohistochemical Quality Control
(NordiQC) external quality assessment (EQA) of p57, run 41,
data from 121 laboratories were used to evaluate p57 Abs for
diagnosing HM. An insufficient result was achieved by 21% of
the laboratories, mostly due to a weak staining reaction or a
poor signal to noise ratio (www.nordiqc.org/downloads/
assessments/41_61.pdf). The NordiQC challenge primarily
compares the analytical performance of p57 staining in par-
ticipating laboratories across various antibodies (Abs) used
with many different protocols and various stainer platforms.21
To evaluate the performance of the Abs more accurately, a
standardized comparison in a reference laboratory is necessary.
In this study, we present a method to assess p57 Abs
for diagnosing HM in a standardized way and illustrate its
use on the 3 best performing p57 Abs from the NordiQC
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challenge, run 41, and a newly launched p57 Ab. Further,
we explored the expression of p57 in syncytiotrophoblasts.
MATERIAL AND METHODS
Tissue Samples
Three tissue microarrays (TMAs) were constructed
from archival paraffin blocks: one with tissue from 5
pregnancy products that morphologically were classified
as CHM and genetically showed 2 paternal genome sets
(CHM;PP), 1 with tissue from 5 pregnancy products that
morphologically were PHM and genetically showed trip-
loidy with 2 paternal genome sets and 1 maternal genome
set (PHM;PPM), and 1 with tissue from 5 morphologically
nonmolar pregnancy products with diploid biparental
genomes (non-HM;PM). The morphologic diagnoses were
made using standard histopathologic criteria.3 The genetic
analyses were performed on unfixed tissue (Supplementary
Material, Part A, Supplemental Digital Content 1, http://
links.lww.com/AIMM/A244). From each pregnancy prod-
uct, 3 cores containing cytotrophoblasts, syncytiotropho-
blasts, and villous stromal cells, and 1 or 2 cores containing
maternal decidual cells and/or intermediate trophoblasts,
respectively, were selected (Supplementary Material, Part
B, Supplemental Digital Content 1, http://links.lww.com/
AIMM/A244).
Analysis of Staining
Four Abs were assessed: mouse monoclonal (mm) Ab
57P06, rabbit monoclonal (rm) Ab EP183, mmAb KP10, and
mmAb KP39, using protocols optimized in a reference labo-
ratory (Supplementary Material, Part C, Supplemental Digital
Content 1, http://links.lww.com/AIMM/A244). The process for
evaluating the performance of the Abs is illustrated in Figure 1.
Using a digital monitor, images of the individual TMA
cores stained with the 4 Abs were viewed simultaneously and
assessed by 3 authors (A.G. and H.L.; pathologists with special
interest in molar diseases; S.N., histology technician and
specialist in immunohistochemistry). For the cytotrophoblasts
and syncytiotrophoblasts, 100 nuclei were assessed. For the
villous stromal cells, maternal decidual cells, and intermediate
trophoblasts, a minimum of 20 nuclei were assessed. For 1/5
cases of PHM;PPM,maternal decidual cells were not available.
For 2/5 cases of PHM;PPM and 3/5 cases of non-HM;PM,
intermediate trophoblasts were not available. For all pregnancy
products, either maternal decidual cells or intermediate
trophoblasts or both were available. The proportion of
stained nuclei, the intensity of the nuclear staining, and the
intensity of the cytoplasmatic staining were categorized using
the criteria shown in Table 1. Categorization was performed by
consensus between the 3 assessors.
Evaluation of the Performance of the Antibodies
For each of the 15 pregnancy products, and each of
the 4 cell types, cytotrophoblasts, villous stromal cells,
maternal decidual cells, and intermediate trophoblasts, the
results of the assessments were quantified by assigning an
individual score, as described in Table 2. A total score was
calculated by summing the individual scores for each of
these cell types in each of the 15 pregnancy products.
FIGURE 1. Flow chart for evaluating the performance of antibodies against p57. *Cytotrophoblasts, villous stromal cells, maternal
decidual cells, and/or intermediate trophoblasts. **CHM;PP, PHM;PPM, non-HM; PM. CHM indicates complete hydatidiform mole;
PHM: partial hydatidiform mole; Non-HM, non-hydatidiform mole; PP: diploid with 2 paternal genome sets; PPM: triploid with 2
paternal genome sets and 1 maternal genome set; PM: diploid with biparental genome.
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In the final evaluation of the Abs, both individual and total
scores were used (Table 3). The p57 staining in the syncytiotro-
phoblasts was evaluated separately (Supplementary Material,
Part D, Supplemental Digital Content 1, http://links.lww.com/
AIMM/A244).
RESULTS
The total scores for the 4 Abs are summarized in
Table 4. Supplementary Material, Part E (Supplemental
Digital Content 1, http://links.lww.com/AIMM/A244) lists the
individual scores. With 57P06, a weak staining of the cyto-
plasm was observed in a number of cases, resulting in the
individual score “2.” However, the cytoplasmatic staining in
no case interfered with the interpretation of the nuclear stain-
ing. The final evaluation for 57P06 was optimal, as the total
score was ≥2/3 of the maximum score, and no individual
score was <2 (Figs. 2A, B).
A maximum individual score was observed for EP183
in the cytotrophoblasts of the 5 cases of CHM;PP (Fig. 2C),
as there was no nuclear or cytoplasmatic staining. In the
cytotrophoblasts and villous stromal cells for both cases of
PHM;PPM (Fig. 2D) and non-HM;PM, the individual score
was ≥2, as the nuclear staining was moderate to strong in
≥50% of the cells. However, in 4/5 cases of CHM;PP, 10% to
49% of the nuclei in villous stromal cells showed staining with
a moderate intensity (Fig. 2C), and in 1 CHM;PP, ≥50% of
the nuclei in villous stromal cells showed moderate staining.
Accordingly, the final evaluation for EP183 was poor.
For KP10, the total score was ≥ 2/3 of the maximum
score, and no individual score was <2 for cytotrophoblasts
and villous stromal cells (Figs. 2E, F). However, 4/24
individual scores for the maternal decidual cells and
intermediate trophoblasts were “1” primarily due to a
moderate staining in the cytoplasm (inset, Fig. 2E). The
final evaluation was good.
KP39 showed moderate cytoplasmatic staining in
villous stromal cells in 2 cases of CHM;PP (Figs. 2G, H)
and strong cytoplasmatic staining in the cytotrophoblasts
in 2 cases of non-HM;PM, interfering with the evaluation
of the staining in the nuclei. The final evaluation was poor.
In all cases of CHM;PP, the frequency of stained
nuclei in cytotrophoblasts was <1% with all 4 Abs,
whereas even with the optimal/good performing Abs
57P06 and KP10, 1% to 9% of the nuclei in villous stromal
cells were stained in several pregnancy products.
Supplementary Material, Part D (Supplemental
Digital Content 1, http://links.lww.com/AIMM/A244) lists the
findings in the syncytiotrophoblasts. With KP39, all 15 preg-
nancy products showed a strong staining of the cytoplasm,
making it difficult to evaluate the nuclear staining (Figs. 2G,
H). With 57P06, EP183, and KP10, all cases of CHM;PP
uniformly showed <1% stained nuclei. In contrast, most nuclei
in PHM;PPM and non-HM;PM showed weak-moderate
staining, with a tendency toward a higher proportion of
stained nuclei and a more extensive staining in the latter.
DISCUSSION
We present a method for evaluation of the perfor-
mance of Abs against p57 for diagnosing HMs and used
this to evaluate 4 p57 Abs. We also explored the ex-
pression of p57 in various cell types, including the syncy-
tiotrophoblasts.
The strengths of our study are the conduction of p57
staining in a reference laboratory. Optimizing protocols
for the Abs and comparing slides on a monitor, allowing
TABLE 1. Categories for Assessment of the Staining With p57
for Diagnosing Hydatidiform Mole
Proportion of nuclei stained < 1%; 1%-9%; 10%-49%; ≥ 50%
Intensity of nuclear staining None; weak; moderate; strong
Intensity of cytoplasmatic staining None; weak; moderate; strong
TABLE 2. Individual Scores Based on the Assessment of the
Staining Reaction of the p57 Antibodies in Various Types of
Pregnancy Products and Various Cell Types
Proportion of Nuclei Stained
Intensity of
Nuclear Staining*
Intensity of
Cytoplasmatic
Staining < 1%
1%-
9%
10%-
49% ≥ 50%
CHM;PP (cytotrophoboblasts and villous stromal cells)
None 3 2 0 0
Weak 2 2 0 0
Moderate 1 1 0 0
Strong 0 0 0 0
CHM;PP (maternal decidual cells and intermediate trophoblasts),
PHM: PPM, and non-HM;PM (all cell types)
None/weak None 0 0 0 0
Weak 0 0 0 0
Moderate 0 0 0 0
Strong 0 0 0 0
Moderate/strong None 0 0 2 3
Weak 0 0 2 2
Moderate 0 0 1 1
Strong 0 0 0 0
*The intensity of the nuclear staining in the cytotrophoblasts and villous
stromal cells in CHM;PP are not included in the assessment.
CHM indicates complete hydatidiform mole; Non-HM, non-hydatidiform
mole; PHM, partial hydatidiform mole; PM, diploid with biparental genome;
PP, diploid with 2 paternal genome sets; PPM, triploid with 2 paternal genome sets
and 1 maternal genome set.
TABLE 3. Final Evaluation of the p57 Antibodies
Criteria Result
Total score ≥ 2/3 of the maximum total score, and no
individual score <2 (all cell types*)
Optimal
Total score ≥ 2/3 of the maximum total score, and ≥ 1
individual score= 1 ( maternal decidua and/or intermediate
trophoblasts) and no individual score <2 (cytotrophoblasts
and villous stromal cells)
Good
Total score ≥ 1/3, <2/3 of the maximum total score,
and no individual score= 0 (all cell types*)
Borderline
Total score <1/3 of the maximum total score, and/or
≥ 1 individual score= 0 (all cell types*)
Poor
*Cytotrophoblasts, villous stromal cells, maternal decidual cells, and inter-
mediate trophoblasts.
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the assessors to observe the same area stained with the
different Abs, contributed to a fair comparison of the Abs.
Testing the antibodies on molar and nonmolar pregnancy
products, well characterized both morphologically and
genetically, further supports the validity of the results. The
use of TMAs consisting of several cores compared with
conventional slides containing more tissue, and the fact that
only one staining platform was used, may have introduced
limitations.
In the algorithm for using IHC of p57 in the diag-
nostics of HM and pregnancy products suspected of being
HM, it is recommended to analyze cytotrophoblasts, villous
stromal cells, maternal decidual cells, and intermediate
trophoblasts.22,23 Our method for evaluating the perfor-
mance of Abs used for p57 staining is based on the as-
sessment of the staining of these 4 cell types, in 3 types of
pregnancy products. In our method, 3 variables are as-
sessed: the proportion of nuclei stained, the intensity of the
nuclear staining, and the intensity of the cytoplasmatic
staining.
To convert IHC results into quantitative data, the
H-score is widely used.24–26 The H-score is calculated by
summing up the products of the percentage of stained
nuclei and the staining intensity. However, as the pro-
portion of stained nuclei is a main criteria in the algorithm
rather than the staining intensity,22 the H-score is not ideal
for assessing p57 Abs. In our method, the staining in the
nuclei and the cytoplasm in the various cell types are
quantitated in individual scores, influenced by the fraction
of nuclei stained and the intensity of the staining sepa-
rately. For the final evaluation, both the individual and
the total scores are used.
The validity of the nuclear staining is important in
every cell type used in the diagnosis of HM. However, this
is most important for cytotrophoblasts and villous stromal
cells, as a staining of ≥ 10% of the nuclei in these cells will
argue against the diagnosis CHM;PP. This is critical, as
the risk of GTN is high for CHM;PP. In this study, the
staining result for EP183 was poor, mainly because the
proportion of stained nuclei in the villous stromal cells
was ≥ 10% in all cases of CHM;PP. It is recommended
that a conceptus showing negative nuclear staining in the
cytotrophoblasts and a simultaneous positive nuclear
staining in the villous stromal cells is investigated further
by genotyping.22 However, genotyping is costly, and not
all laboratories have access to this technique. Thus, when
validating p57 Abs, the staining in the various cell types
should be assessed separately.
Most authors apparently do not assess staining in the
cytoplasm in their evaluation of HM.10,16,18,20,27 However,
excessive nonspecific cytoplasmatic staining has been sug-
gested to influence the nuclear staining, which could lead to
erroneous interpretation.23 For cells serving as positive
controls, we allowed a moderate cytoplasmatic staining for
the final evaluation as good. However, to avoid misjudgment
of the nuclear staining, an Ab showing moderate staining of
the cytoplasm in cytotrophoblasts or villous stromal cells
could at the most achieve a borderline result in the final
evaluation. The cytoplasmatic staining was of significance
for the final evaluation of 2 of the 4 antibodies. For KP10, a
moderate staining in the cytoplasm in maternal decidual cells
and/or intermediate trophoblasts that could interfere with
the interpretation of the nuclear staining, was the main
reason for the final evaluation resulting good, but not opti-
mal. For KP39, a moderate to strong cytoplasmatic staining
in cytotrophoblasts and villous stromal cells interfering with
the evaluation of the nuclear staining was the main cause
that the final evaluation ended up as poor. These findings
illustrate that assessment of the staining in the cytoplasm is
important.
TABLE 4. Total Scores for the Staining Reaction With the 4 p57 Antibodies
Scores for Individual Abs
Type of Pregnancy Type of Cells Maximum Score 57P06 EP183 KP10 KP39
CHM;PP Cytotrophoblasts 15 12 15 11 10
Villous stromal cells 15 11 0 11 6
Maternal decidual cells 15 10 8 9 10
Intermediate trophoblasts 15 11 10 10 11
Sum 60 44 33 41 37
PHM;PPM Cytotrophoblasts 15 12 14 11 15
Villous stromal cells 15 15 14 15 15
Maternal decidual cells* 12 8 7 8 8
Intermediate trophoblasts* 9 6 6 6 7
Sum 51 41 41 40 45
Non-HM;PM Cytotrophoblasts 15 10 11 11 4
Villous stromal cells 15 14 12 13 10
Maternal decidual cells 15 10 7 9 11
Intermediate trophoblasts* 6 4 4 3 3
Sum 51 38 34 36 28
Total score 162 123 108 117 110
Final evaluation Optimal Poor Good Poor
The total score was obtained by summing up the individual scores for the various cell types for CHM;PP, PHM;PPM, and non-HM;PM.
*For PHM;PPM and non-HM;PM: <5 cores represented the maternal decidual cells and/or intermediate trophoblasts.
CHM indicates complete hydatidiform mole; Non-HM, non-hydatidiform mole; PHM, partial hydatidiform mole; PM, diploid with biparental genome; PP, diploid with
2 paternal genome sets; PPM, triploid with 2 paternal genome sets and 1 maternal genome set.
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In the NordiQC challenge, the proportion of laboratories
with sufficient results (optimal or good) was 100% (14/14) for
KP10, 83% (5/6) for KP39, and 82% (32/39) for 57P06 (www.
nordiqc.org/downloads/assessments/41_61.pdf). In the present
study, we evaluated the staining result for KP10 as good, for
KP39 as poor, and for 57P06 as optimal. In the NordiQC
challenge, run 41, serial sections of TMAs of “standardly
processed” tissues were circulated to a number of laboratories
to be stained with the p57 Ab routinely used in the laboratory,
and they were thereafter assessed by a group of experienced
pathologists and biomedical scientists. Thus, the results from
the NordiQC challenge were based on the various protocols
and IHC staining systems used by the participating labo-
ratories. In our study, we performed a standardized compar-
ison of p57 Abs using in-house optimized versions of the
vendor’s protocols. We obtained the best staining result with
57P06 in contrast to only 82% of the laboratories obtaining a
sufficient result in the NordiQC challenge. Our observations
suggest that this Ab can be recommended for diagnosing HMs,
if the protocol is optimized.
In the NordiQC challenge, KP10 showed the best
performance. With this Ab, we found a moderate staining
in the cytoplasm in the maternal decidual cells and the
intermediate trophoblasts. Accordingly, our final evalua-
tion for KP10 was good, but not optimal. Probably, in the
NordiQC challenge, there was less focus on the cyto-
plasmatic staining, compared with our assessment. Being
aware of the potential staining in the cytoplasm in the
internal controls, KP10 is acceptable for diagnosing HMs.
In the NordiQC challenge, 5/6 laboratories obtained a
sufficient result with KP39. In our study, KP39 was evaluated
as poor, mainly because of a strong cytoplasmatic staining in
the cytotrophoblasts and villous stromal cells in some sam-
ples. In the NordiQC challenge, no comments on strong
cytoplasmatic staining with this Ab were made. As the
NordiQC challenge was performed in 2014, other lots may
have been used, giving different staining reactions. To search
for the explanation of the discrepancy, we purchased KP39
with another lot number from the same vendor. However,
again, we observed an unacceptable strong cytoplasmatic
staining (data not shown). This does not exclude that some
lots of this Ab may perform well. However, as at least some
lots seem to cause a cytoplasmatic staining interfering with the
interpretation of the nuclear staining in cells that should be
negative in CHM;PP, this antibody cannot be recommended.
Furthermore, with this antibody, the cytoplasm of the syn-
cytiotrophoblasts showed strong staining in all cases of CHM;
PP, PHM;PPM, and non-HM;PM. For an unexperienced
pathologist, the strong staining in the syncytiotrophoblasts
may interfere with the interpretation of the staining in
neighboring cytotrophoblasts.
Neither can the new Ab EP183 be recommended for
diagnosing HMs. The positive staining in the nuclei in the
villous stromal cells in CHM;PP is problematic, as these should
be negative. Therefore, a CHM;PP could be overlooked.
Diagnostics of mosaics, characterized by both p57-positive and
p57-negative cells,28,29 also require reliable p57 staining in the
various cell types.
As NordiQC is an EQA system, it can identify per-
formance problems in the individual laboratories. However,
both internal and external quality control for diagnostic IHC
are important.30–32
The method presented here complements the Nor-
diQC challenge, because using optimized protocols and
rigorous standardized assessments can reveal the reasons
for suboptimal staining results. Further, our method can
be used by individual laboratories to assess which p57 Ab
performs best in their set-up.
FIGURE 2. P57 staining with the Abs 57P06 (A, B), EP183 (C, D), KP10 (E, F), and KP39 (G, H). A, Immunostaining with the Ab
57P06 in a CHM;PP (case 1). There is no staining in the nuclei of the cytotrophoblasts (score 3), and 1% to 9% stained nuclei with a
weak staining intensity in the villous stromal cells (score 2). As a positive internal control, the intermediate trophoblasts showed a
strong staining in ≥50% of the nuclei and a weak cytoplasmatic staining (inset, score 2). In the syncytiotrophoblasts, there is no
nuclear staining, but a weak cytoplasmatic staining. B, Immunostaining staining with the Ab 57P06 in a PHM;PPM (case 6). There
is a strong nuclear staining in ≥50% of the nuclei and a weak cytoplasmatic staining in the cytotrophoblasts (score 2), and ≥50%
stained nuclei with strong staining intensity in the villous stromal cells (score 3). In the syncytiotrophoblasts, there is a weak nuclear
staining in 1% to 9% of the nuclei and a weak cytoplasmatic staining. C, Immunostaining with the Ab EP183 in a CHM;PP (case 1).
There is a moderate nuclear staining in 10% to 49% of the villous stromal cells (score 0). Both in the cytotrophoblasts and the
syncytiotrophoblasts, neither nuclei nor cytoplasm are stained (score 3). D, Immunostaining with the Ab EP183 in a PHM;PPM
(case 6). There is a strong staining in ≥50% of the nuclei in the cytotrophoblasts and the villous stromal cells (score 3). The
cytoplasm is clear in these cells. In the syncytiotrophoblasts, there is a weak nuclear staining in 10% to 49% of the nuclei, and no
cytoplasmatic staining. E, Immunostaining with the Ab KP10 in a CHM;PP (case 1). There is no nuclear staining, but a weak
cytoplasmatic staining in the cytotrophoblasts (score 2). In the villous stromal cells, there is a weak staining in 1% to 9% of the
nuclei (score 2). In the decidual cells, ≥50% of the nuclei were strongly stained; however, the cytoplasm showed moderate
staining (inset, score 1), which was a main cause of the final evaluation resulting good. There is no nuclear staining, but a weak
cytoplasmatic staining in the syncytiotrophoblasts. F, Immunostaining with the Ab KP10 in a PHM;PPM (case 6). The cyto-
trophoblasts showed a strong staining in ≥50% of the nuclei and a weak cytoplasmatic staining (score 2). Likewise, the nuclear
staining is strong in ≥50% of the villous stromal cells, and the cytoplasm is clear in these cells (score 3). In the syncytiotropho-
blasts, there is a weak staining in 1% to 9% of the nuclei, and a weak cytoplasmatic staining. G and H, Immunostaining with the Ab
KP39 in 2 cases of CHM;PP (G: case 2, H: case 1). There is a moderate cytoplasmatic staining in the villous stromal cells interfering
with the evaluation of the nuclear staining in these cells (in both cases: score 0). There is no nuclear staining, but a weak
cytoplasmatic staining in the cytotrophoblasts (in both cases: score 2). Furthermore, there is a very strong cytoplasmatic staining in
the syncytiotrophoblasts complicating the evaluation of the nuclear staining in these cells.
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The interpretation of the p57 staining is described as
straightforward in the majority of cases, as the nuclei in the
cell types in which p57 is differentially expressed, should be
stained almost uniformly negative or positive.22 However, a
limited extent of nuclear p57 staining has previously been
reported in the cytotrophoblasts and villous stromal cells in
CHMs, and therefore <10% stained nuclei are considered
compatible with a diagnosis of CHM.10,15 In all cases of
CHM;PP, and with all Abs, we observed staining of <1% of
the nuclei of cytotrophoblasts, whereas, in some cases, 1% to
9% of the nuclei in the villous stroma were stained. It is
possible that the paternal imprinting of CDKN1C is more
“constant” in the cytotrophoblasts than in the villous stro-
mal cells; however, we cannot exclude that, in some cases, a
“foreign cell” present in the villus was mistaken as a villous
stromal cell. Although our observations suggest that the cut-
off for cytotrophoblasts could be lowered to 1%, we suggest
that the limit 10% is maintained in order to minimize the risk
of misclassifying a CHM;PP.
With antibodies against p57, the nuclei of the syn-
cytiotrophoblasts in HMs and early non-HM pregnancy
products have been reported to be uniformly negative
10,11,15 or occasionally immunoreactive.14,27 With 57P06,
KP10, and EP183, we observed staining of <1% of the
nuclei in the syncytiotrophoblasts in all cases of CHM;PP,
while some nuclear staining was observed in most cases of
PHM;PPM and non-HM;PM, with a tendency for more
frequent staining of the latter. The absence of staining in
CHM;PP indicates that CDKN1C is paternally imprinted
and maternally expressed in the syncytiotrophoblasts,
whereas the apparent difference between the staining in
non-HM;PM and HM;PPM is at present unexplained.
A small percentage of diploid HMs show mosaicism
between a diploid cell line with 2 paternal genome sets and
a normal biparental cell line (PP/PM). Accordingly, the
phenotype of these HMs may not be that of a “classic”
CHM. However, as these moles impose a risk of GTN
similar to the risk after a CHM;PP,33 it is important to
identify the mosaic HMs. In mosaic HMs, discordant
immunostaining of p57, for example, absence of staining
in the villous stromal cells and presence of staining in the
cytotrophoblasts, or vice versa, has been described.22,28,29
Thus, it could be tempting to include the staining pattern
of the nuclei in the syncytiotrophoblasts in the diagnostics.
However, in that case, one should pay attention to the fact
that, in the presence of a maternally inherited allele of
CDKN1C, the staining of nuclei of the syncytiotropho-
blasts generally appear both weaker and less consistent
than the staining of the nuclei of the cytotrophoblasts and
the villous stromal cells.
CONCLUSIONS
We present a method for estimating the quality of
p57 Abs for diagnosing HMs, wherein both the staining of
nuclei and of cytoplasm are assessed, and wherein both the
staining of nuclei expected to be positive and that of nuclei
expected to be negative are assessed. Among 4 Abs tested,
we found the Ab 57P06 to be best. However, for optimal
results, each laboratory should repeat the testing to vali-
date the performance with the IHC methods used in the
local laboratory. CDKN1C seems paternally imprinted
and maternally expressed in the syncytiotrophoblasts.
However, for clinical use, nuclear staining of p57 in the
syncytiotrophoblasts should be interpreted with caution,
as the nuclear staining of syncytiotrophoblasts with a
maternal allele of CDKN1C can be weak.
REFERENCES
1. Szulman AE, Surti U. The syndromes of hydatidiform mole. II.
Morphologic evolution of the complete and partial mole. Am J Obstet
Gynecol. 1978;132:20–27.
2. Sebire NJ, Makrydimas G, Agnantis NJ, et al. Updated diagnostic
criteria for partial and complete hydatidiform moles in early
pregnancy. Anticancer Res. 2003;23:1723–1728.
3. Sebire NJ. Histopathological diagnosis of hydatidiform mole:
contemporary features and clinical implications. Fetal Pediatr Pathol.
2010;29:1–16.
4. Kajii T, Ohama K. Androgenetic origin of hydatidiform mole.
Nature. 1977;268:633–634.
5. Kovacs BW, Shahbahrami B, Tast DE, et al. Molecular genetic
analysis of complete hydatidiform moles. Cancer Genet Cytogenet.
1991;54:143–152.
6. Niemann I, Hansen ES, Sunde L. The risk of persistent trophoblastic
disease after hydatidiform mole classified by morphology and ploidy.
Gynecol Oncol. 2007;104:411–415.
7. Joergensen MW, Niemann I, Rasmussen AA, et al. Triploid
pregnancies: genetic and clinical features of 158 cases. Am J Obstet
Gynecol. 2014;211:370.e1–370.e19.
8. Savage PM, Sita-Lumsden A, Dickson S, et al. The relationship of
maternal age to molar pregnancy incidence, risks for chemotherapy
and subsequent pregnancy outcome. J Obstet Gynaecol (Lahore).
2013;33:406–411.
9. Fukunaga M. Immunohistochemical characterization of p57Kip2
expression in tetraploid hydropic placentas. Arch Pathol Lab Med.
2004;128:897–900.
10. Castrillon DH, Sun D, Weremowicz S, et al. Discrimination of
complete hydatidiform mole from its mimics by immunohistochem-
istry of the paternally imprinted gene product p57KIP2. Am J Surg
Pathol. 2001;25:1225–1230.
11. Jun S-Y, Ro JY, Kim K-R. P57Kip2 is useful in the classification
and differential diagnosis of complete and partial hydatidiform
moles. Histopathology. 2003;43:17–25.
12. Landolsi H, Missaoui N, Brahem S, et al. The usefulness of p57
KIP22 immunohistochemical staining and genotyping test in the diagnosis
of the hydatidiform mole. Pathol Res Pract. 2011;207:498–504.
13. Madi JM, Braga A, Paganella MP, et al. Accuracy of p57KIP2-
compared with genotyping to diagnose complete hydatidiform mole: a
systematic review and meta-analysis. BJOG An Int J Obstet Gynaecol.
2018;125:1226–1233.
14. Chilosi M, Piazzola E, Lestani M, et al. Differential expression of
p57kip2, a maternally imprinted cdk inhibitor, in normal human
placenta and gestational trophoblastic disease. Lab Invest. 1998;78:
269–276.
15. Fukunaga M. Immunohistochemical characterization of p57 KIP2
expression in early hydatidiform moles.Hum Pathol. 2002;33:1188–1192.
16. Crisp H, Burton JL, Stewart R, et al. Refining the diagnosis of
hydatidiform mole: image ploidy analysis and p57KIP2 immunohis-
tochemistry. Histopathology. 2003;43:363–373.
17. Popiolek DA, Yee H, Mittal K, et al. Multiplex short tandem repeat
DNA analysis confirms the accuracy of p57KIP2 immunostaining in
the diagnosis of complete hydatidiform mole. Hum Pathol. 2006;37:
1426–1434.
18. McConnell TG, Murphy KM, Hafez M, et al. Diagnosis and
subclassification of hydatidiform moles using p57 immunohistochemistry
and molecular genotyping: validation and prospective analysis in routine
and consultation practice settings with development of an algorithmic
approach. Am J Surg Pathol. 2009;33:805–817.
Lund et al Appl Immunohistochem Mol Morphol  Volume 28, Number 9, October 2020
700 | www.appliedimmunohist.com Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
19. Vang R, et al. Diagnostic reproducibility of hydatidiform moles:
ancillary techniques (p57 immunohistochemistry and molecular
genotyping) improve morphologic diagnosis. Am J Surg Pathol. 2012;
36:443–453.
20. Banet N, DeScipio C, Murphy KM, et al. Characteristics of hydatidiform
moles: analysis of a prospective series with p57 immunohistochemistry and
molecular genotyping. Mod Pathol. 2014;27:238–254.
21. Vyberg M, Nielsen S. Proficiency testing in immunohistochemistry—
experiences from Nordic Immunohistochemical Quality Control
(NordiQC). Virchows Arch. 2016;468:19–29.
22. Ronnett BM, DeScipio C, Murphy KM. Hydatidiform moles:
ancillary techniques to refine diagnosis. Int J Gynecol Pathol. 2011;30:
101–116.
23. Ronnett BM. Hydatidiform moles: ancillary techniques to refine
diagnosis. Arch Pathol Lab Med. 2018;142:1485–1502.
24. McCarty KS, Miller LS, Cox EB, et al. Estrogen receptor analyses.
Correlation of biochemical and immunohistochemical methods using
monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:
716–721.
25. Fedchenko N, Reifenrath J. Different approaches for interpretation
and reporting of immunohistochemistry analysis results in the bone
tissue—a review. Diagn Pathol. 2014;9:221.
26. Borrisholt M, Nielsen S, Vyberg M. Demonstration of CDX2 is
highly antibody dependant. Appl Immunohistochem Mol Morphol.
2013;21:64–72.
27. Abdou A, Kandil M, El-Wahed MA, et al. The diagnostic value of
p27 in comparison to p57 in differentiation between different
gestational trophoblastic diseases. Fetal Pediatr Pathol. 2013;32:
395–411.
28. Hoffner L, Dunn J, Esposito N, et al. P57KIP2 immunostaining and
molecular cytogenetics: combined approach aids in diagnosis of
morphologically challenging cases with molar phenotype and in
detecting androgenetic cell lines in mosaic/chimeric conceptions.
Hum Pathol. 2008;39:63–72.
29. Lewis GH, DeScipio C, Murphy KM, et al. Characterization
of androgenetic/biparental mosaic/chimeric conceptions, inclu-
ding those with a molar component: morphology, p57 immnohis-
tochemistry, molecular genotyping, and risk of persistent
gestational trophoblastic disease. Int J Gynecol Pathol. 2013;32:
199–214.
30. Lin F, Chen Z. Standardization of diagnostic immunohistochemis-
try: literature review and Geisinger experience. Arch Pathol Lab
Med. 2014;138:1564–1577.
31. Nielsen S. External quality assessment for immunohistochemistry:
experiences from NordiQC. Biotech Histochem. 2015;90:331–340.
32. Cates JMM, Troutman KA. Quality management of the immuno-
histochemistry laboratory: a practical guide. Appl Immunohistochem
Mol Morphol. 2015;23:471–480.
33. Sunde L, Niemann I, Hansen ES, et al. Mosaics and moles. Eur J
Hum Genet. 2011;19:1026–1031.
Appl Immunohistochem Mol Morphol  Volume 28, Number 9, October 2020 p57 in Hydatidiform Moles
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. www.appliedimmunohist.com | 701
